COLL Collegium Pharmaceutical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: COLL

Price (delayed)

$18.01

Market cap

$614.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1

Enterprise value

$1.24B

Collegium Pharmaceutical Inc. is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts.

Highlights
COLL's debt has surged by 167% year-on-year but it is down by 2.9% since the previous quarter
The quick ratio has declined by 40% year-on-year but it rose by 5% since the previous quarter
Collegium Pharmaceutical's EPS has plunged by 183% from the previous quarter and by 133% YoY
The net income has plunged by 182% from the previous quarter and by 133% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.collegiumpharma.com
Peers: ENDP AGRX HZNP UTHR

Key stats

What are the main financial stats of COLL
Market
Shares outstanding
34.13M
Market cap
$614.61M
Enterprise value
$1.24B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.1
Price to sales (P/S)
1.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.97
Earnings
Revenue
$313.51M
EBIT
-$18.86M
EBITDA
-$16.19M
Free cash flow
$67.23M
Per share
EPS
-$1
Free cash flow per share
$1.98
Book value per share
$5.82
Revenue per share
$9.22
TBVPS
$13.77
Balance sheet
Total assets
$1.25B
Total liabilities
$1.05B
Debt
$754.91M
Equity
$197.61M
Working capital
-$5.32M
Liquidity
Debt to equity
3.82
Current ratio
0.99
Quick ratio
0.78
Net debt/EBITDA
-38.9
Margins
EBITDA margin
-5.2%
Gross margin
46.5%
Net margin
-11.2%
Operating margin
-6%
Efficiency
Return on assets
-3.6%
Return on equity
-16.6%
Return on invested capital
-4%
Return on capital employed
-2.3%
Return on sales
-6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

COLL stock price

How has the Collegium Pharmaceutical stock price performed over time
Intraday
0.28%
1 week
-8.99%
1 month
8.95%
1 year
-12.23%
YTD
-3.59%
QTD
1.64%

Financial performance

How have Collegium Pharmaceutical's revenue and profit performed over time
Revenue
$313.51M
Gross profit
$145.64M
Operating income
-$18.88M
Net income
-$35.25M
Gross margin
46.5%
Net margin
-11.2%
The net income has plunged by 182% from the previous quarter and by 133% YoY
COLL's net margin has dropped by 171% since the previous quarter and by 134% year-on-year
Collegium Pharmaceutical's operating margin has shrunk by 127% YoY and by 20% QoQ
Collegium Pharmaceutical's operating income has shrunk by 126% YoY and by 39% QoQ

Growth

What is Collegium Pharmaceutical's growth rate over time

Valuation

What is Collegium Pharmaceutical stock price valuation
P/E
N/A
P/B
3.1
P/S
1.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.97
Collegium Pharmaceutical's EPS has plunged by 183% from the previous quarter and by 133% YoY
The price to book (P/B) is 38% lower than the 5-year quarterly average of 5.0
The equity is down by 22% year-on-year
COLL's price to sales (P/S) is 54% lower than its 5-year quarterly average of 4.2 and 11% lower than its last 4 quarters average of 2.2
The revenue is up by 15% since the previous quarter but it has declined by 3.9% year-on-year

Efficiency

How efficient is Collegium Pharmaceutical business performance
The ROE has shrunk by 188% QoQ and by 130% YoY
The company's return on assets has shrunk by 172% QoQ and by 122% YoY
Collegium Pharmaceutical's ROS has plunged by 127% YoY and by 20% from the previous quarter
The ROIC has plunged by 111% YoY and by 8% from the previous quarter

Dividends

What is COLL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COLL.

Financial health

How did Collegium Pharmaceutical financials performed over time
Collegium Pharmaceutical's total assets is 19% more than its total liabilities
Collegium Pharmaceutical's total liabilities has surged by 127% YoY
Collegium Pharmaceutical's total assets has soared by 75% YoY
COLL's debt has surged by 167% year-on-year but it is down by 2.9% since the previous quarter
The equity is down by 22% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.